A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Amgen Inc (NASDAQ: AMGN) over alleged securities laws violations and a deadline to submit the settlement claim is …
You don't need me to tell you that there are two parts to any trade. First, for long trades, we have to buy something. Then, to actually turn paper profits into real money, we have to sell it. To me, biotech giant Amgen …
Among the S&P 500’s biggest fallers on Wednesday December 07 was Amgen Inc. (AMGN). The stock experienced a 2.7% decline to $141.19 with 7.02 million shares changing hands. Amgen Inc. started at an …
N/A Shares Held by All Insider and 5% Owners N/A % of Shares Held by Institutional & Mutual Fund Owners N/A % of Float Held by Institutional & Mutual Fund Owners
The aftermath of the Allergan divestiture and acquisition event is currently being digested by Wall Street, because the repercussions are likely to be larger than just the single day news. The move by Allergan is a …
Allergan
The positive results will bring more competition in osteoporosis therapeutic market Amgen, Inc. (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) announced that romosozumab has shown strong positive results in the …
AstraZeneca (NYSE:AZN) is buying privately-held Guangdong BeiKang Pharmaceutical. It is a Chinese maker of generic injectable antibiotics, for an undisclosed sum. The purchase consolidates AZN’s No. 2 position in …
Submitted by The Life Sciences Report as part of our contributors program. This interview was conducted by George S. Mack of The Life Sciences Report (4/25/13) Dick Huebner knows what he wants. He’s looking for …
Amgen (NASDAQ:AMGN) today announced that the FOURIER trial evaluating whether Repatha (evolocumab) …
CARDIOVASCULAR EVENTS